TST801

N/A

Report date: 2026/01/05 17:17:47

First In Class

Base Information

Drug NameTST801

Drug Alias NameTST-801TST801

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionAnti-B-cell-activating factor/B lymphocyte stimulatorTumor necrosis factor ligand superfamily member 13 modulators

TargetsB-cell-activating factor/B lymphocyte stimulatorTumor necrosis factor ligand superfamily member 13

Therapy Area/IndicationsLupus Erythematosus, SystemicLupus NephritisGlomerulonephritis, IGA

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesTranscenta Holding Ltd

China Registration ClassN/A

Develop Information

Active CompaniesTranscenta Holding Ltd

Inactive CompaniesN/A

Active IndicationsLupus Erythematosus, SystemicLupus NephritisGlomerulonephritis, IGA

Inactive IndicationsN/A

Other Information

ATC CodeN/A